NSCLC
Oncology · 2006–2026
79decisions
28medicines
47carried consumer input
195individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amivantamab Treatment of patients with epidermal growth factor receptor gene mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (NSCLC) where the… | Mar 2026 | Recommended with restriction | no section in document |
| osimertinib First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with evidence of an activating epidermal growth factor… | Sep 2025 | Recommended with restriction | no section in document |
| osimertinib Unresectable locally advanced (Stage III) EGFR pathogenic variant positive non-small cell lung cancer (NSCLC) whose disease has not progressed during or… | Jul 2025 | Recommended with restriction | input received Thoracic Oncology Group · Medical Oncology Group Australia · Lung Foundation Australia · Rare Cancers Australia |
| osimertinib First-line treatment of patients with locally advanced (Stage IIIB/C) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with evidence of activating… | May 2025 | Not recommended | input received |
| amivantamab and lazertinib First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with evidence of activating epidermal growth factor… | Mar 2025 | Not recommended | 74 individuals Rare Cancers Australia |
| dabrafenib and trametinib Treatment of adult patients with advanced (metastatic) Stage IV non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. | Mar 2025 | Recommended with restriction | 3 individuals Lung Foundation Australia · Rare Cancers Australia · Rare Caners Australia · Medical Oncology Group |
| encorafenib Advanced or metastatic non-small cell lung cancer (Stage IV NSCLC) with a BRAF V600E mutation who have not received prior systemic treatment in the metastatic… | Nov 2025 | Recommended with restriction | 1 individuals |
| selpercatinib Advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adults aged 18 years or older. | Jul 2024 | Recommended with restriction | input received |
| atezolizumab Subcutaneous injection formulation for multiple cancer indications including locally advanced or metastatic NSCLC, stage IV metastatic NSCLC, extensive-stage… | Mar 2024 | Recommended with restriction | input received Rare Cancers Australia · Lung Foundation Australia |
| bevacizumab Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced… | Mar 2024 | Recommended with restriction | 1 individuals |
| nivolumab Neoadjuvant treatment of surgically-resectable non-small cell lung cancer (NSCLC) in patients with node-positive disease or tumours at least 4 cm in size. | Mar 2024 | Deferred | input received Lung Foundation Australia · Medical Oncology Group |
| nivolumab Perioperative treatment (neoadjuvant plus adjuvant) of patients with resectable non-small cell lung cancer (tumours ≥4 cm or node positive) without known EGFR… | Dec 2024 | Not recommended | input received |
| amivantamab First-line treatment of adults with locally advanced or metastatic NSCLC with activating EGFR exon 20 insertion mutations, in combination with platinum-based… | Nov 2024 | Recommended | 14 individuals Rare Cancers Australia · Lung Foundation Australia |
| mobocertinib Adults with locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor exon 20… | Jul 2023 | Recommended with restriction | 2 individuals Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| nivolumab Neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy. | Jul 2023 | Recommended | input received Lung Foundation Australia |
| nivolumab Neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC) (tumours ≥4 cm or node positive) in combination with platinum-based… | Mar 2023 | Not recommended | input received Lung Foundation Australia · Rare Cancers Australia · Medical Oncology Group |
| pemetrexed Patients with malignant pleural mesothelioma or locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. | Mar 2023 | Recommended with restriction | input received Lung Foundation Australia |
| cemiplimab First-line treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 aberrations, in combination… | Nov 2023 | Recommended with restriction | input received Lung Foundation Australia |
| osimertinib Adjuvant therapy after surgical resection in patients with Stage IB to IIIA EGFR mutation-positive non-small cell lung cancer (NSCLC). | Nov 2023 | Recommended with restriction | 1 individuals Lung Foundation Australia |
| atezolizumab Adjuvant treatment in patients with Stage II-IIIA PD-L1 positive non-small cell lung cancer following complete resection and platinum-based chemotherapy. | Jul 2022 | Recommended with restriction | input received Lung Foundation Australia · Medical Oncology Group · Lung Foundation |
| durvalumab Treatment of unresectable Stage III non-small cell lung cancer (NSCLC) in patients who have received platinum-based chemoradiation therapy and have not… | Mar 2022 | Recommended | input received Lung Foundation Australia · Rare Cancers Australia |
| sotorasib Treatment of patients with non-squamous or not otherwise specified (NOS) Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer… | Mar 2022 | Not recommended | input received |
| mobocertinib Adults with epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) positive locally advanced or metastatic (Stage IIIB/IV) non-small cell lung… | Nov 2022 | Not recommended | input received Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| lorlatinib Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with evidence of an anaplastic lymphoma kinase (ALK) gene… | Jul 2021 | Deferred | input received Medical Oncology Group |
| bevacizumab Treatment of non-small cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel for first-line treatment of patients with unresectable advanced,… | Mar 2021 | Recommended with restriction | input received Lung Foundation Australia |
| nivolumab Treatment of non-small cell lung cancer (NSCLC) following progression or after prior chemotherapy (second-line NSCLC). | Mar 2021 | Not recommended | none received |
| lorlatinib Treatment of patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with evidence of an anaplastic lymphoma… | Dec 2021 | Recommended | input received Medical Oncology Group |
| bevacizumab Biosimilar bevacizumab indicated for the same indications as the reference product Avastin, including first-line treatment of patients with Stage IV… | Nov 2021 | Recommended with restriction | unclear |
| cemiplimab First-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with high PD-L1 expression (tumour proportion score ≥50%), who are EGFR… | Nov 2021 | Recommended with restriction | 2 individuals Medical Oncology Group · Lung Foundation Australia · Rare Cancers Australia |
| tepotinib Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations (METex14sk). | Nov 2021 | Recommended | input received |
| osimertinib First-line treatment of locally advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer with activating epidermal growth factor receptor… | Jul 2020 | Recommended with restriction | unclear |
| nivolumab plus ipilimumab First-line treatment of previously untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC) in patients without EGFR or ALK gene rearrangements, in… | Nov 2020 | Recommended with restriction | input received Lung Foundation · Medical Oncology Group · Cancer Network |
| pembrolizumab Previously untreated Stage IV non-small cell lung cancer (NSCLC) without targetable mutations. | Aug 2019 | Recommended with restriction | no section in document |
| durvalumab Treatment of Stage III unresectable non-small cell lung cancer (NSCLC) in patients who have not progressed after platinum-based chemoradiation therapy. | Jul 2019 | Not recommended | unclear |
| pembrolizumab First-line treatment of patients with Stage IV non-squamous non-small cell lung cancer (NSCLC) who are EGFR wild-type, negative for ALK or ROS1 gene… | Jul 2019 | Recommended with restriction | 2 individuals |
| alectinib Treatment of stage IIIB (locally advanced) or stage IV (metastatic) non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement. | Mar 2019 | Not recommended | 3 individuals |
| atezolizumab Treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with bevacizumab and platinum-doublet chemotherapy. Two… | Mar 2019 | Recommended with restriction | input received |
| pembrolizumab First-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1 at Tumour Proportion Score (TPS) ≥50%. | Mar 2019 | Noted | no section in document |
| alectinib, crizotinib, ceritinib Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) positive for ALK gene rearrangement (alectinib, crizotinib,… | Nov 2019 | Recommended with restriction | no section in document |
| atezolizumab Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with disease progression on or after prior… | Nov 2019 | Recommended with restriction | 1 individuals |
| durvalumab Treatment of unresectable Stage III non-small cell lung cancer (NSCLC) for patients whose disease has not progressed following chemoradiation therapy (CRT). | Nov 2019 | Recommended with restriction | 2 individuals |
| osimertinib Locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients who have progressed on or after prior EGFR tyrosine… | Jul 2018 | Deferred | 29 individuals |
| pembrolizumab First-line treatment of patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumours do not have an activating EGFR gene mutation or… | Jul 2018 | Recommended with restriction | 10 individuals |
| pembrolizumab First-line treatment of patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumours do not have an activating EGFR gene mutation or… | Mar 2018 | Deferred | 4 individuals |
| durvalumab Stage III unresectable non-small cell lung cancer (NSCLC) in patients who have not progressed after platinum-based chemoradiation therapy, as consolidation… | Nov 2018 | Not recommended | input received Medical Oncology Group |
| osimertinib Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on or after prior… | Nov 2018 | Recommended with restriction | 5 individuals |
| pembrolizumab First-line treatment of patients with Stage IV non-squamous NSCLC with EGFR wild type and ALK translocation negative status, when used in combination with… | Nov 2018 | Not recommended | 2 individuals |
| crizotinib Treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). | Mar 2017 | Recommended | none received |
| nivolumab Non-squamous cell non-small cell lung cancer (NSCLC) and squamous cell NSCLC in patients who have failed platinum-based chemotherapy. | Mar 2017 | Recommended with restriction | none received |
| pembrolizumab First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients without activating EGFR or ALK gene alterations and with… | Mar 2017 | Not recommended | 11 individuals |
| atezolizumab Locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have disease progression on or after prior platinum-based chemotherapy. | Nov 2017 | Recommended with restriction | 2 individuals |
| crizotinib Treatment of patients with locally advanced (Stage IIIB) or metastatic (Stage IV) ROS1-positive non-squamous NSCLC or histology not otherwise specified NSCLC,… | Nov 2017 | Deferred | 7 individuals Rare Cancers Australia |
| osimertinib Locally advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with EGFR T790M mutation-positive disease following progression on or… | Nov 2017 | Recommended with restriction | 19 individuals |
| pembrolizumab First-line treatment of patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumours do not have an activating EGFR gene mutation or… | Nov 2017 | Deferred | input received Medical Oncology Group |
| pemetrexed Treatment of patients with malignant pleural mesothelioma in combination with cisplatin; initial treatment of locally advanced or metastatic non-small cell… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pemetrexed Treatment of locally advanced or metastatic non-small cell lung cancer (after prior platinum-based chemotherapy) and malignant pleural mesothelioma (in… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pembrolizumab Locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with high programmed death ligand 1 (PD-L1) expression (tumour proportion score… | Nov 2016 | Not recommended | input received Medical Oncology Group · Lung Foundation |
| afatinib dimaleate First or subsequent line treatment of locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion… | Jul 2015 | Not recommended | none received |
| crizotinib Treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) as second-line therapy following disease… | Mar 2014 | Deferred | input received Medical Oncology Group |
| afatinib First-line treatment of locally advanced (stage IIIB) or metastatic (stage IV) non-squamous or not otherwise specified non-small-cell lung cancer (NSCLC) in… | Jul 2013 | Not recommended | unclear |
| afatinib Second/third-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with progressive disease after prior platinum… | Jul 2013 | Not recommended | no section in document |
| erlotinib Initial and continuing first-line treatment, as monotherapy, of locally advanced (stage IIIB) or metastatic (stage IV) non-squamous or not otherwise specified… | Jul 2013 | Not recommended | unclear |
| gefitinib First-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations. | Jul 2013 | Recommended | unclear |
| erlotinib Initial and continuing first-line treatment, as monotherapy, of locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) in… | Jul 2012 | Not recommended | unclear |
| gefitinib First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with an activating mutation(s) of the epidermal growth… | Nov 2012 | Not recommended | unclear |
| gefitinib First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with EGFR-activating mutations. | Nov 2012 | Recommended with restriction | unclear |
| bevacizumab initial treatment, in combination with carboplatin and paclitaxel, of a patient with advanced or metastatic non-squamous non-small cell lung cancer who meet… | Mar 2011 | Not recommended | unclear |
| pemetrexed first line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with predominantly non-squamous cell histology in combination with… | Mar 2010 | Not recommended | no section in document |
| gefitinib First-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with an activating mutation of the EGFR gene. | Nov 2010 | Not recommended | no section in document |
| Pemetrexed First-line treatment of non-small-cell-lung cancer (NSCLC) with non-squamous cell histology in combination with cisplatin. | Mar 2009 | Recommended with restriction | no section in document |
| pemetrexed disodium First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with predominantly non-squamous cell histology in combination with… | Nov 2009 | Recommended with restriction | no section in document |
| erlotinib Treatment as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) where disease progression has occurred following… | Nov 2007 | Recommended | no section in document |
| pemetrexed Use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma. Also indicated for the treatment of locally advanced or… | Nov 2007 | Recommended with restriction | no section in document |
| erlotinib Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy and have disease… | Nov 2007 | Recommended | no section in document |
| erlotinib Treatment of patients with locally advanced or metastatic non-small cell lung cancer who have previously received chemotherapy. | Mar 2006 | Recommended | no section in document |
| vinorelbine tartrate locally advanced or metastatic non-small cell lung cancer | Mar 2006 | Recommended with restriction | no section in document |
| erlotinib hydrochloride Treatment of patients with locally advanced or metastatic non-small cell lung cancer who have previously received chemotherapy. | Mar 2006 | Recommended | no section in document |
| vinorelbine tartrate Locally advanced or metastatic non-small cell lung cancer (NSCLC) as first-line treatment. | Mar 2006 | Recommended with restriction | no section in document |
| erlotinib Treatment as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a WHO status of 3 or less where disease… | Nov 2006 | Not recommended | no section in document |
Who spoke
Lung Foundation Australia · Medical Oncology Group · Rare Cancers Australia · Lung Foundation · Lung Cancer Foundation Australia · Rare Caners Australia · Cancer Network · Thoracic Oncology Group · Medical Oncology Group Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 47 of 59 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.